Pfizer Inc.announced that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5...
Objectives: To assess consistency of treatment effects of tofacitinib versus placebo in subgroups defined by baseline characteristics, and to ascertain whether baseline characteristics are of value in optimizing tofacitinib use.
Pfizer Inc. announced top-line results from two pivotal Phase III trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT...
Pfizer has announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor...
To investigate the CV risk factors and major adverse cardiovascular events (MACE) in patients with active Psoriatic Arthritis (PsA) receiving...
Introduction: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and 2 extension studies found that Ilumya offers sustained and improved results in patients with moderate-to-severe plaque psoriasis who received treatment for up to four years with no new safety concerns recorded.
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected.
Sun Pharmaceuticals presented positive, five-year Phase III data for Ilumya (tildrakizumab-asmn) from the combined reSURFACE 1 and reSURFACE 2 extension studies.